© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses the need for practice-wide education concerning biosimilars in cancer care.
Transcript
There has to be a practice-wide campaign for everyone in the care chain to understand biosimilars. So, when it comes to infusion nurses, they understand they're giving a different drug, but it's in the same class. And so, when we're changing drugs, we get an informed consent for these patients so they know it's a new drug. When we're starting new, the infusion nurses are just hanging them just like any other drug.